Shalby Ltd

Q1 FY27Healthcare Services

Shalby Ltd Q1 FY27 Results & Concall Highlights: Revenue ₹47 Cr, PAT ₹10.5 Cr

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹157

Market cap₹1.7K Cr

P/E42.0

Updated26 Aug 2026

Read4 min read

What the Q1 FY27 call signalled

3 of 4 strong

RevenueRank 3

MarginRank 1

CapexYes

FundraiseYes

Not discussed on this call: order book.

The short version

Shalby MedTech showed strong revenue growth: ₹47 crores in Q1 FY27, a 53% YoY increase. Shalby expects improved profitability and operating leverage across its portfolio, aiming for sustained growth in earnings.

From Shalby Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.

Revenue & Sales Performance

Rank 3

Shalby MedTech showed strong revenue growth: ₹47 crores in Q1 FY27, a 53% YoY increase.
India operations grew 98% YoY, showing increasing product demand and improving execution.
US business sales remained stable with modest 9% YoY growth; multiple initiatives in progress to boost US sales.
MedTech business aims to sustain strong growth momentum with a maintained CAGR of 93%.
Hospital segment occupancy improved, with a 9.8% YoY increase in occupied beds and expected EBITDA margin rise to ~20%.
Gurgaon unit achieved EBITDA breakeven, with further occupancy growth expected.
New specialties and doctor recruitment underway to drive further hospital revenue growth.
Overall, management is confident of improving profitability and revenue growth across segments in coming quarters.

Profitability & Margins

Shalby expects improved profitability and operating leverage across its portfolio, aiming for sustained growth in earnings.
Hospital segment margins are anticipated to improve, targeting an EBITDA margin upward of 20% for FY27.
The Gurgaon unit has achieved EBITDA break-even and is expected to sustain and grow profitability in coming quarters.
MedTech business shows strong revenue growth (53% YoY) with EBITDA turning positive for four consecutive quarters, signaling improving operating earnings.
Internal initiatives are driving cost reductions (e.g., ₹3 crores per month reduction in cash flow requirement in MedTech).
Consolidated PAT improved to ₹10.5 crores in Q1 FY27, up from ₹7.7 crores YoY, indicating strong growth in net profits.
ROCE is currently around 7% consolidated, expected to improve to industry standards (11%-13%) within 1-2 years.
Management projects stable or reducing net debt, supporting future earnings growth without increased financial burden.

See what Shalby Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes

- **Mumbai Expansion (Asha Parekh Hospital, 200 beds):** Planned as a greenfield project with cash CAPEX outlay expected around April 2027. Investment benchmarks and funding sources (debt vs internal accruals) will be assessed once finalized. No additional debt infusion anticipated for existing hospitals or MedTech for now. - **MedTech Business:** Continuing selective investments in products and technologies for sustainable long-term growth; recent CAPEX already deployed, including bunker facility and robotics. Minimal CAPEX planned going forward. - **Operational Efficiencies:** Initiatives underway to reduce cash flow requirements by ~₹3 crores per month through operational improvements and vendor partnerships in MedTech. - **Working Capital & Inventory Optimization:** Ongoing focus on inventory optimization and cash conversion cycle improvements with automated tools and stronger follow-ups. Overall, strategic investments are focused on capacity expansion in Mumbai and enhancing MedTech capabilities with a disciplined CAPEX approach.

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹981 Cr

Rev 1Mar 1

2CHANDAN₹518 Cr

Rev 1Mar 3

3₹66.5K Cr

Rev 2Mar 1

4₹654 Cr

Rev 2Mar 2

5₹1.3L Cr

Rev 2Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

No new fresh debt infusion is planned currently.
Recent ₹129 crores working capital facility from Kotak is a replacement of existing debt at a better cost (30 basis points lower), not an increase.
Net debt levels are stable or expected to reduce in coming quarters, with no increase anticipated.
For the planned Mumbai greenfield hospital expansion (200 beds at Asha Parekh Hospital), cash CAPEX outlay and funding approach will be assessed upon finalization.
Management indicated possible use of internal accruals or debt but no definitive fundraising decision yet.
No further debt infusion is expected into the Gurgaon hospital or MedTech units.
Overall, debt profile is being managed with focus on efficient cost and stable or reducing net debt.

See what Shalby Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly mention the current or expected order book or pending orders for Shalby Limited. However, relevant points that indicate business momentum and future growth include: - Strong consolidated revenue growth of 11.6% YoY reaching ₹338.6 crores in Q1 FY27. - MedTech business revenue grew about 53% YoY. - Significant growth in occupancy and revenue in hospital units such as Krishna, Mohali, and Naroda (approx. 30% YoY growth). - Ongoing initiatives including new doctor recruitment, specialties deployment likely to boost revenue further. - Discussions and plans underway for Mumbai expansion with 200-bed Asha Parekh Hospital development. - Active efforts to improve government scheme renewals and TPA tie-ups which could increase volumes. - The company is focused on selective investments in products and technology for sustainable long-term growth. No specific order book or pending orders value has been disclosed in the transcript.

Shalby Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹287 Cr, net profit ₹18 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Shalby Ltd's management said in earlier quarters

Others in Healthcare Services this season

Manipal Health Enterprises Ltd (Q1 FY27)
Volume-led growth with inpatient (IP) volumes up 39% and outpatient (OP) volumes up 26% year-on-year. Key concall takeaways from Manipal Health Enterprises…
Fortis Healthcare Ltd (Q1 FY27)
IHH plans to increase its stake in Fortis to over 50% within 3-5 years, supporting long-term strategic growth. Key concall takeaways from Fortis Healthcare…
Metropolis Healthcare Ltd (Q1 FY27)
East India currently 6%, with limited investment so far; future investments may increase contribution. Key concall takeaways from Metropolis Healthcare Ltd's…
Apollo Hospitals Enterprise Ltd (Q1 FY27)
IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare Institute Ltd vs Manipal Health Enterprises Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Shalby Ltd Q1 FY27 results?

What is Shalby Ltd share price analysis?

Shalby Ltd currently shows a below-average growth signal. The stock trades at a P/E of 42.0 with a market cap of ₹1,652 Cr. Investors should review the full earnings analysis for detailed insights.

Is Shalby Ltd planning capital expenditure?

Mumbai Expansion (Asha Parekh Hospital, 200 beds):** Planned as a greenfield project with cash CAPEX outlay expected around April 2027.

Keep Shalby Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.